All Cases

Case Information
Resilience at InterMune: A Journey Through the Valley of the Shadow of Death
Bahrami, Homa
Publication date: 6/10/2015, pages 1-29

This case is about California-based biotechnology company, InterMune, that despite many setbacks, ultimately succeeded in developing an orphan drug used to treat a deadly lung disease. In 2014, InterMune was acquired by Roche/Genentech for $8.3 billion, a significant premium over it's trading price. With resilience, InterMune’s CEO, Dan Welch, led through numerous strategic pivots, leadership changes, clinical trial disappointments, multiple divestitures, and ultimately the sale of the company. Specifically, Welch sharpened InterMune’s strategic focus on a few indications, evolved the Board and the leadership team, and orchestrated a grassroots initiative to re-invent InterMune’s core values and cultural pillars.
 


Educators may request a complimentary preview before purchasing. To find out more, please read about our Copyright Permission Request Form.


Berkeley Haas Case Series

A new collection of business case studies from Berkeley Haas

The aim of the Berkeley Haas Case Series is to incite business innovation by clarifying disruptive trends and questioning the status quo.

Learn more
Follow Us